|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||12.40 - 13.15|
|52-week range||4.65 - 51.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Mar 2022 - 14 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
LONDON, December 15, 2021--Kanabo, one of Europe’s fastest-growing medical cannabis and R&D companies that focuses on the distribution of cannabis-derived products for medical patients, and wellness CBD consumers, today announced that its unique CBD and nicotine formula has moved from Patent Cooperation Treaty (PCT) phase to National Phase in the US, UK, and EU countries - the last phase before becoming an internationally approved patent.
LONDON, October 07, 2021--Kanabo, one of Europe’s fastest-growing medical cannabis R&D companies that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, has signed a partnership agreement with the Medocann Pharma Ltd. to develop new products that will target specific medical conditions. The deal gives Kanabo exclusive distribution rights to the co-developed products into the growing German and UK cannabis markets.